Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...

Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

treatment Spinraza (nusinersen), which has seen its growth stalled by rival therapies entering the market. It is also in the midst of a planned $7.3 billion takeover of Reata Pharma, aimed at ...

Zolgensma will compete against another highly expensive drug - Biogen's Spinraza (nusinersen), while Roche is also developing a potential rival called risdiplam that is slated for a European ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Eisai (ESAIY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has approved the Supplemental Biologics License ...

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 23.Invest with Confidence: ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: January 24 at 7:55:27 p.m. EST ...

The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months. The FDA has accepted a supplemental ...